495 related articles for article (PubMed ID: 38319331)
1. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
Plumb ID; Briggs Hagen M; Wiegand R; Dumyati G; Myers C; Harland KK; Krishnadasan A; James Gist J; Abedi G; Fleming-Dutra KE; Chea N; Lee JE; Kellogg M; Edmundson A; Britton A; Wilson LE; Lovett SA; Ocampo V; Markus TM; Smithline HA; Hou PC; Lee LC; Mower W; Rwamwejo F; Steele MT; Lim SC; Schrading WA; Chinnock B; Beiser DG; Faine B; Haran JP; Nandi U; Chipman AK; LoVecchio F; Eucker S; Femling J; Fuller M; Rothman RE; Curlin ME; Talan DA; Mohr NM;
Vaccine; 2024 Apr; 42(10):2543-2552. PubMed ID: 37973512
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Wang LF; Ren EC; Lye DC; Tan KB
Lancet Infect Dis; 2023 Dec; 23(12):1343-1348. PubMed ID: 37543042
[TBL] [Abstract][Full Text] [Related]
5. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
6. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
7. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.
Fleming-Dutra KE; Ciesla AA; Roper LE; Smith ZR; Miller JD; Accorsi EK; Verani JR; Shang N; Derado G; Wiegand RE; Pilishvili T; Britton A; Link-Gelles R
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):177-182. PubMed ID: 36795625
[TBL] [Abstract][Full Text] [Related]
8. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
9. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
Fowlkes AL; Yoon SK; Lutrick K; Gwynn L; Burns J; Grant L; Phillips AL; Ellingson K; Ferraris MV; LeClair LB; Mathenge C; Yoo YM; Thiese MS; Gerald LB; Solle NS; Jeddy Z; Odame-Bamfo L; Mak J; Hegmann KT; Gerald JK; Ochoa JS; Berry M; Rose S; Lamberte JM; Madhivanan P; Pubillones FA; Rai RP; Dunnigan K; Jones JT; Krupp K; Edwards LJ; Bedrick EJ; Sokol BE; Lowe A; McLeland-Wieser H; Jovel KS; Fleary DE; Khan SM; Poe B; Hollister J; Lopez J; Rivers P; Beitel S; Tyner HL; Naleway AL; Olsho LEW; Caban-Martinez AJ; Burgess JL; Thompson MG; Gaglani M
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):422-428. PubMed ID: 35298453
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents.
Oliveira CR; Niccolai LM; Sheikha H; Elmansy L; Kalinich CC; Grubaugh ND; Shapiro ED;
JAMA Netw Open; 2022 Mar; 5(3):e220935. PubMed ID: 35238933
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
13. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.
Kim RK; Choe YJ; Jang EJ; Chae C; Hwang JH; Lee KH; Shim JA; Kwon GY; Lee JY; Park YJ; Lee SW; Kwon D
J Korean Med Sci; 2023 Nov; 38(46):e396. PubMed ID: 38013649
[TBL] [Abstract][Full Text] [Related]
16. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.
Zambrano LD; Newhams MM; Simeone RM; Payne AB; Wu M; Orzel-Lockwood AO; Halasa NB; Calixte JM; Pannaraj PS; Mongkolrattanothai K; Boom JA; Sahni LC; Kamidani S; Chiotos K; Cameron MA; Maddux AB; Irby K; Schuster JE; Mack EH; Biggs A; Coates BM; Michelson KN; Bline KE; Nofziger RA; Crandall H; Hobbs CV; Gertz SJ; Heidemann SM; Bradford TT; Walker TC; Schwartz SP; Staat MA; Bhumbra SS; Hume JR; Kong M; Stockwell MS; Connors TJ; Cullimore ML; Flori HR; Levy ER; Cvijanovich NZ; Zinter MS; Maamari M; Bowens C; Zerr DM; Guzman-Cottrill JA; Gonzalez I; Campbell AP; Randolph AG;
MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):330-338. PubMed ID: 38635481
[TBL] [Abstract][Full Text] [Related]
17. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
[TBL] [Abstract][Full Text] [Related]
18. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.
; Thompson MG; Yoon SK; Naleway AL; Meece J; Fabrizio TP; Caban-Martinez AJ; Burgess JL; Gaglani M; Olsho LEW; Bateman A; Lundgren J; Grant L; Phillips AL; Groom HC; Stefanski E; Solle NS; Ellingson K; Lutrick K; Dunnigan K; Wesley MG; Guenther K; Hunt A; Mak J; Hegmann KT; Kuntz JL; Bissonnette A; Hollister J; Rose S; Morrill TC; Respet K; Fowlkes AL; Thiese MS; Rivers P; Herring MK; Odean MJ; Yoo YM; Brunner M; Bedrick EJ; Fleary DE; Jones JT; Praggastis J; Romine J; Dickerson M; Khan SM; Lamberte JM; Beitel S; Webby RJ; Tyner HL
JAMA; 2022 Oct; 328(15):1523-1533. PubMed ID: 36255426
[TBL] [Abstract][Full Text] [Related]
19. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
Surie D; DeCuir J; Zhu Y; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Ali H; Taghizadeh L; Gong MN; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Columbus C; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Hart KW; Swan SA; Lewis NM; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1625-1630. PubMed ID: 36580424
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
